A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups

Kikuchi, Takashi; Gittins, John
August 2011
Statistical Methods in Medical Research;Aug2011, Vol. 20 Issue 4, p389
Academic Journal
The behavioural Bayes approach to sample size determination for clinical trials assumes that the number of subsequent patients switching to a new drug from the current drug depends on the strength of the evidence for efficacy and safety that was observed in the clinical trials. The optimal sample size is the one which maximises the expected net benefit of the trial. The approach has been developed in a series of papers by Pezeshk and the present authors (Gittins JC, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 2000; 34: 355—63; Gittins JC, Pezeshk H. How Large should a clinical trial be? The Statistician 2000; 49(2): 177—87; Gittins JC, Pezeshk H. A decision theoretic approach to sample size determination in clinical trials. Journal of Biopharmaceutical Statistics 2002; 12(4): 535—51; Gittins JC, Pezeshk H. A fully Bayesian approach to calculating sample sizes for clinical trials with binary responses. Drug Information Journal 2002; 36: 143—50; Kikuchi T, Pezeshk H, Gittins J. A Bayesian cost-benefit approach to the determination of sample size in clinical trials. Statistics in Medicine 2008; 27(1): 68—82; Kikuchi T, Gittins J. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety. Statistics in Medicine 2009; 28(18): 2293—306; Kikuchi T, Gittins J. A Bayesian procedure for cost-benefit evaluation of a new drug in multi-national clinical trials. Statistics in Medicine 2009 (Submitted)). The purpose of this article is to provide a rationale for experimental designs which allocate more patients to the new treatment than to the control group. The model uses a logistic weight function, including an interaction term linking efficacy and safety, which determines the number of patients choosing the new drug, and hence the resulting benefit. A Monte Carlo simulation is employed for the calculation. Having a larger group of patients on the new drug in general makes it easier to recruit patients to the trial and may also be ethically desirable. Our results show that this can be done with very little if any reduction in expected net benefit.


Related Articles

  • Using the Bernoulli trial approaches for detecting ordered alternatives. Chia-Hao Chang; Chih-Chien Chin; Weichieh Wayne Yu; Ying-Yu Huang // BMC Medical Research Methodology;2013, Vol. 13 Issue 1, p1 

    Background Diagnostic problems in clinical trials are sometimes ordinal. For example, colon tumor staging was performed according to the TNM classification. However, clinical data are limited by markedly small sample sizes in some stage. Methods We propose a distribution-free test for detecting...

  • A MONTE-CARLO ESTIMATION OF EFFECT SIZE DISTORTION DUE TO SIGNIFICANCE TESTING. Bradley, M.T.; Smith, D.; Stoica, G. // Perceptual & Motor Skills;Dec2002, Vol. 95 Issue 3, p837 

    A Monte-Carlo study was done with true effect sizes in deviation units ranging from 0 to 2 and a variety of sample sizes. The purpose was to assess the amount of bias created by considering only effect sizes that passed a statistical cut-off criterion of α = .05. The deviation values obtained...

  • Exploring multi-modal distributions with nested sampling. Feroz, Farhan; Skilling, John // AIP Conference Proceedings;Aug2013, Vol. 1553 Issue 1, p106 

    In performing a Bayesian analysis, two difficult problems often emerge. First, in estimating the parameters of some model for the data, the resulting posterior distribution may be multi-modal or exhibit pronounced (curving) degeneracies. Secondly, in selecting between a set of competing models,...

  • Nested Sampling with Constrained Hamiltonian Monte Carlo. Betancourt, Michael // AIP Conference Proceedings;3/14/2011, Vol. 1305 Issue 1, p165 

    Nested sampling is a powerful approach to Bayesian inference ultimately limited by the computationally demanding task of sampling from a heavily constrained probability distribution. An effective algorithm in its own right, Hamiltonian Monte Carlo is readily adapted to efficiently sample from...

  • Perfect Tempering. Daghofer, M.; von der Linden, W. // AIP Conference Proceedings;2004, Vol. 735 Issue 1, p355 

    Multimodal structures in the probability density can be a serious problem for traditional Markov Chain Monte Carlo (MCMC), because correct sampling of the different structures can only be guaranteed for infinite sampling time. Samples may not decouple from the initial configuration for a long...

  • Bayesian computation in big spaces-nested sampling and Galilean Monte Carlo. Skilling, John // AIP Conference Proceedings;5/3/2012, Vol. 1443 Issue 1, p145 

    We hold this truth to be self-evident, that good principle and good practice go hand in hand. The principles of Bayesian analysis derive from elementary symmetries, and nothing more. In sympathy with those same symmetries, and noting that every invariance broken is generality forgone, we develop...

  • Nested sampling with demons. Habeck, Michael // AIP Conference Proceedings;2015, Vol. 1641 Issue 1, p121 

    This article looks at Skilling's nested sampling from a physical perspective and interprets it as a microcanonical demon algorithm. Using key quantities of statistical physics we investigate the performance of nested sampling on complex systems such as Ising, Potts and protein models. We show...

  • Testing the null of a low dimensional growth model. Jensen, Peter Sandholt // Empirical Economics;Feb2010, Vol. 38 Issue 1, p193 

    Applied growth researchers face a sample with more regressors than observations when using cross-country data. In this paper, we examine simple procedures for testing if a true submodel has been found. Specifically, we examine three tests that can be used to test a low dimensional growth model...

  • A systematic review of models to predict recruitment to multicentre clinical trials. Barnard, Katharine D.; Dent, Louise; Cook, Andrew // BMC Medical Research Methodology;2010, Vol. 10, p63 

    Background: Less than one third of publicly funded trials managed to recruit according to their original plan often resulting in request for additional funding and/or time extensions. The aim was to identify models which might be useful to a major public funder of randomised controlled trials...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics